Oleg I. Krijanovski
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Dr. Oleg I. Krijanovski

Hematology
2001 Dwight Way, 
Berkeley, CA 
On Staff At
Accepting New Patients
Experienced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
2001 Dwight Way, 
Berkeley, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Oleg Krijanovski is a Hematologist in Berkeley, California. Dr. Krijanovski is rated as an Experienced provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Thrombocytopenia, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Waldenstrom Macroglobulinemia, and Bone Marrow Aspiration. Dr. Krijanovski is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Russian State Medical University
Residency
University of Michigan Hospitals
Specialties
Hematology
Licenses
Internal Medicine in MI
Board Certifications
Hematology - Board Certified
Medical Oncology - Board Certified
Fellowships
Residency in Internal Medicine (Clinical Investigator Pathway),Department of Internal Medicine, University of Michigan Cancer Center, Fellowship in Hematology/Oncology/BMT, Department of Internal, Medicine, University of Michigan Cancer Center, Ann Arbor, MI, Post-Doctoral Research Fellow, Pediatric Oncology Department, Dana Farber Cancer Institute, Boston, MA, University of Michigan Hospitals
Hospital Affiliations
Alta Bates Summit Medical Center
Sutter Medical Center, Sacramento
Alta Bates Summit Medical Center - Alta Bates Camp
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
MetLife
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

ABSMC Comprehensive Cancer Center
2001 Dwight Way, Berkeley, CA 94704

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: a Phase III Study
Enrollment Status: Active_not_recruiting
Publish Date: January 10, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Anastrozole
Study Phase: Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 4 Less Clinical Trials

2 Total Publications

Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.
Improved survival after transplantation of more donor plasmacytoid dendritic or naïve T cells from unrelated-donor marrow grafts: results from BMTCTN 0201.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 02, 2014
Similar Doctors
Ranjana H. Advani
Elite in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Ranjana H. Advani
Oncology | Hematology
Elite in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Ranjana H. Advani
Oncology | Hematology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (30.2 miles away)
650-723-4000
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ranjana Advani is an Oncologist and a Hematologist in Stanford, California. Dr. Advani has been practicing medicine for over 43 years and is rated as an Elite provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Her top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy.

Distinguished in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Dita A. Gratzinger
Hematology
Distinguished in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Dita A. Gratzinger
Hematology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (30.2 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances

Dita Gratzinger is a Hematologist in Stanford, California. Dr. Gratzinger is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). Her top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, T-Cell Lymphoma, and Tissue Biopsy.

Advanced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Joseph G. Schroers-Martin
Oncology | Hematology
Advanced in Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)
Dr. Joseph G. Schroers-Martin
Oncology | Hematology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (30.2 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Schroers-Martin is an Oncologist and a Hematologist in Stanford, California. Dr. Schroers-Martin is rated as a Distinguished provider by MediFind in the treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL). His top areas of expertise are Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Follicular Lymphoma, and Non-Hodgkin Lymphoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Krijanovski's expertise for a condition
ConditionClose
    View All 37 Advanced Conditions
    View All 57 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile